Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Earnings release
confidence 98%
filed 2026-08-03
Item 2.02
Douglas Dynamics issued a press release on August 3, 2026 announcing Q2 2026 financial results, including record net sales of $214.6 million (up 10%), net income of $25.4 million, and adjusted diluted EPS of $1.22 (up 7%). The company also raised its 2026 full-year guidance ranges for net sales, adjusted EBITDA, and adjusted diluted EPS. This is a standard quarterly earnings release with material financial performance metrics and forward guidance.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-08-03
Item 1.01
The Company entered into two bridge loan arrangements with its Chairman and CEO totaling $400,000 in principal ($200,000 each in May and July 2026), each bearing 8% annual interest and convertible into equity at the Lender's option. These bridge notes constitute new direct financial obligations with potential dilutive conversion features.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-03
Item 2.02
Independence Realty Trust issued a press release on August 3, 2026 announcing its financial results for the three and six months ended June 30, 2026, including quarterly EPS of $0.01, CFFO per share of $0.28, same-store NOI growth of 1.2%, and affirmed full-year 2026 guidance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-03
Item 2.02
Addus HomeCare disclosed financial results for the second quarter and six months ended June 30, 2026, reporting net service revenues of $377.4 million (8.0% increase), net income of $27.6 million ($1.49 per diluted share), and adjusted EBITDA of $49.2 million (11.9% increase year-over-year).
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-03
Item 2.02
Item 2.02 discloses Tidewater's financial results for the quarter and six months ended June 30, 2026, with revenue of $342.3 million and net income of $21.7 million for Q2 2026, along with updated 2026 guidance. The earnings release is furnished as Exhibit 99.1 and includes detailed financial statements, management commentary, and forward-looking guidance, which is the hallmark of an earnings release disclosure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-03
Item 2.02
HealthStream issued a press release on August 3, 2026 announcing second quarter 2026 financial results, including revenues of $83.7 million (up 12.5%), operating income of $8.3 million (up 41.4%), net income of $6.7 million (up 23.8%), and diluted EPS of $0.23 (up from $0.18), along with updated full-year 2026 guidance.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-08-03
Item 8.01
The Board of Directors declared a quarterly cash dividend of $0.035 per share, payable on August 28, 2026 to holders of record on August 17, 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-03
Item 2.02
This is a straightforward earnings release disclosing National Presto Industries' financial results for the fiscal quarter ended July 5, 2026. The press release, filed as Exhibit 99.1, presents net sales of $146.6 million (up 21.7% YoY), net earnings of $15.9 million (up 207.8% YoY), and EPS of $2.21 (up 207% YoY) for Q2 2026, along with six-month comparative results. The Item 2.02 disclosure and attached exhibit are the standard format for quarterly earnings announcements.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-03
Item 8.01
Dorchester Minerals closed an acquisition of approximately 3,100 net royalty acres of mineral and royalty interests in the Williston Basin, structured as a non-taxable contribution in exchange for the issuance of 835,958 common units. This material acquisition expands the Partnership's asset base with producing and non-producing oil and gas assets.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-03
Item 1.01
Moleculin Biotech entered into a placement agency agreement with Roth Capital Partners for a public offering of 12.4 million shares of common stock (or pre-funded warrants) and 37.1 million common stock purchase warrants at $0.75 per share, raising approximately $9.3 million gross proceeds. This is a dilutive equity issuance that materially increases the share count and dilutes existing shareholders, with the company restricting future issuances for 45–180 days post-closing and insiders subject to 60-day lock-ups.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-08-03
Item 1.01
The disclosure centers on a material amendment to senior secured convertible notes totaling approximately $10.9 million, with the July 2025 Convertible Note extended from July 29, 2026 to August 29, 2026. While technically an amendment to existing debt rather than a new issuance, the amendment to a material direct financial obligation (convertible debt) falls within the debt_issuance category as it involves modification of a significant debt instrument. The materiality is evident from the principal amount and the secured convertible nature of the obligation.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-08-03
Item 8.01
Teads filed a lawsuit against Google LLC and Alphabet Inc. in the U.S. District Court for the Southern District of New York on August 3, 2026, alleging unlawful anticompetitive practices in digital advertising technology markets, including monopolization, illegal tying, and deceptive practices spanning over a decade. The complaint asserts seven counts under Sherman Act and state law, seeking financial damages and other remedies.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-03
Item 2.02
SI-BONE issued a press release on August 3, 2026 announcing Q2 2026 financial results, including revenue of $56.0 million (15.2% YoY growth), improved net loss of $4.1 million (33.6% improvement), and positive adjusted EBITDA of $2.8 million (178% improvement). The company also raised full-year 2026 guidance. This is a standard quarterly earnings release filed under Item 2.02 and attached as Exhibit 99.1, disclosing material financial performance metrics and forward guidance that would affect a reasonable investor's assessment of the company.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-03
Item 2.02
This is a clear earnings release for Golub Capital BDC's third fiscal quarter ended June 30, 2026. The Item 2.02 disclosure explicitly states "Golub Capital BDC, Inc. issued a press release announcing its financial results for its third fiscal quarter ended June 30, 2026," with the full press release attached as Exhibit 99.1. The release includes selected financial highlights, net investment income per share ($0.33), earnings per share ($0.22), NAV per share ($14.25), and detailed portfolio and operational results—all hallmarks of a quarterly earnings announcement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-03
Item 2.02
This Item 2.02 disclosure announces Golub Capital BDC's financial results for the third fiscal quarter ended June 30, 2026, with an earnings presentation attached as Exhibit 99.1. The presentation contains comprehensive quarterly financial metrics including net asset value per share ($14.25), net investment income per share ($0.34), earnings per share ($0.22), portfolio performance data, credit quality metrics, and dividend declarations—all hallmarks of a quarterly earnings release. The company explicitly states it will host a conference call on August 4, 2026 to discuss these results.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-03
Item 5.02
Mark V. Anquillare was appointed as a director of Teladoc Health, effective August 3, 2026, and concurrently appointed to the audit and compensation committees. The Board determined he qualifies as an independent director and audit committee financial expert.
View raw filing on EDGAR →
8-K
Operational Other
confidence 80%
filed 2026-08-03
Item 1.01
Edible Garden entered into a multi-year supply agreement with Meijer Distribution, a major Midwest big-box retailer, effective January 1, 2027 through December 31, 2028, covering hydroponic, potted, and fresh cut herbs with annually renegotiated pricing and flexible delivery schedules. This material commercial contract strengthens a key retail partnership and expands the company's private label business across the Midwest.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-03
Item 2.01
On August 2, 2026, Sharing Economy International Inc. (a shell company) completed a reverse acquisition of Light Across, Inc. through a Share Exchange Agreement, issuing 4,998,838,436 shares (80% of post-transaction shares) to Light Across stockholders. The transaction transforms SEII from a shell company into an operating electric vehicle engineering, design, and manufacturing company, with Light Across becoming a wholly-owned subsidiary and Ximing Huang (SEII's CEO and Chairman) acquiring approximately 65.6% beneficial ownership.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-03
Item 2.02
This is a standard quarterly earnings release for Q2 2026 (ended June 30, 2026) filed on August 3, 2026. The Item 2.02 disclosure announces financial results including revenues of $901.6 million, net income of $89.1 million, diluted GAAP EPS of $0.97, and raised 2026 guidance. The press release is attached as Exhibit 99.1 with detailed financial tables and management commentary, which is the typical format for earnings_release classifications.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-03
Item 2.02
Sabra Health Care REIT reported second quarter 2026 financial results on August 3, 2026, disclosing a net loss of $(0.10) per diluted share, FFO of $(0.02), Normalized FFO of $0.38, and AFFO of $0.39, along with consolidated financial statements and operational metrics including EBITDARM coverage ratios and investment activity.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-03
The filing discloses a non-brokered private placement of 33.4 million Series A-2 Preferred Shares, comprised of 20.8 million shares issued for US$5.2 million in new cash and 12.6 million shares issued in exchange for cancellation of Series A-1 shares. The unregistered securities were issued pursuant to exemptions from Securities Act registration requirements (Item 3.02), and the company has raised approximately US$14.5 million in aggregate gross proceeds across all closings. This is a classic dilutive equity issuance to raise capital.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-03
The 8-K discloses results of Palatin Technologies' annual meeting of stockholders held on July 28, 2026, under Item 5.07. The filing reports voting outcomes on four matters: election of four directors (Carl Spana, John Prendergast, Alan Dunton, and Arlene Morris), ratification of KPMG LLP as independent auditor, approval of a 260,000-share increase to the 2011 Stock Incentive Plan, and advisory approval of named executive officer compensation. All four proposals passed with substantial majorities. This is a standard shareholder vote results disclosure material to investors' understanding of governance and capital allocation.
View raw filing on EDGAR →
8-K
Workforce Reduction
confidence 85%
filed 2026-08-03
The filing discloses a company-wide cost reduction plan announced on August 3, 2026, that includes a reduction in force affecting approximately 7 positions (5% of global workforce) and approximately $2.4 million in annualized SG&A expense reductions. The press release explicitly states "The Plan includes a reduction in force affecting approximately 7 positions, or approximately 5% of the Company's global workforce. Approximately 40% expected cash spend reduction is attributable to the reduction in force." This is a material operational restructuring with associated exit costs that would affect a reasonable investor's assessment of the company's cost structure and path to positive cash flow.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-08-03
Item 7.01
MDWerks' subsidiary RF Specialties has signed a non-binding Letter of Intent with Rex Lumber Company to form a proposed joint venture focused on developing and commercializing radio frequency-based solutions for the lumber industry. The LOI establishes a 51%-49% ownership structure, with Rex Lumber committing a "substantial multi-million-dollar initial capital investment" and potential board representation. While non-binding, this represents a material strategic transaction that would create a new joint venture entity and accelerate commercialization of the company's technology platform into a new market segment.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-03
The filing discloses receipt of official FDA minutes from a Type C meeting regarding alignment on the design of an adaptive Phase 2 field study for TNX-4800 (anti-OspA monoclonal antibody) for Lyme disease prevention. This represents a material regulatory milestone and clinical development advancement—the company has secured FDA agreement on key study design elements (3,300 participants, randomized placebo-controlled design, primary efficacy endpoint at six months) and plans to initiate the Phase 2 study in Q1 2027. While this is a significant operational and regulatory event for a clinical-stage biopharmaceutical company, it does not fit neatly into the specific event categories (not an earnings release, executive change, M&A activity, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, litigation, debt issuance, dividend, or workforce reduction). The event is clearly operational/strategic in nature—a material product development milestone—making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-03
The filing discloses an unregistered private placement of 5,474,053 shares of common stock to OPKO Health at $0.9134 per share for $5.0 million gross proceeds, exempt under Section 4(a)(2) and Regulation D. This is a classic dilutive equity issuance that would materially affect a reasonable investor's assessment of ownership dilution and capital structure, particularly given the significant share count increase and the involvement of a related party (Dr. Phillip Frost, who is co-founder and principal stockholder of Cocrystal).
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-03
EX-99.1
This shareholder letter announces Fast Track's strategic pivot toward an IP and media business model, including two co-branded partnership agreements with Sony Music Entertainment Malaysia and the launch of LAUNCHPAD (a recurring live entertainment circuit) and a Global Digital Content Platform. The company discloses securing 100% IP ownership of developed content and 90% net profit share, representing a material shift in business strategy and revenue model. While not a discrete M&A transaction, partnership, or operational restructuring fitting narrower categories, this strategic repositioning and platform launch constitute a material operational and strategic business event affecting the company's future direction and earnings potential.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-03
The 8-K discloses unaudited financial results for Q2 and first half 2026 via a press release titled "QHSLab (OTCQB:USAQ) Reports Second Quarter and First Half 2026 Unaudited Financial Results." The filing includes detailed financial highlights showing revenue growth (40.1% YoY in Q2), improved gross margins, operating income, and net income turnaround, along with management commentary on business performance and strategy. This is a classic earnings release disclosure under Item 7.01 (Regulation FD Disclosure).
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-03
The filing discloses an operational and strategic update on Bitmine's digital asset accumulation strategy, including ETH holdings reaching 5.8 million tokens (4.8% of total ETH supply), total crypto and cash holdings of $11.3 billion, a 4.5 million share repurchase in the past week, and expansion of the MAVAN staking platform. While the press release contains forward-looking statements about the "Alchemy of 5%" ETH acquisition goal and projected staking revenues, the core disclosure is an operational update on the company's treasury strategy and business activities rather than a specific event type (earnings, M&A, impairment, etc.). This is material to investors assessing the registrant's strategic positioning and asset accumulation progress.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-03
EX-99.1
The exhibit announces that J-Star has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement, following a hearing on July 21, 2026. The company's ordinary shares maintained a closing bid price of at least $1.00 per share for 10 consecutive trading sessions, resolving the delisting risk. This is a material disclosure because it directly addresses a continued listing standard and the resolution of a prior compliance deficiency that threatened the company's Nasdaq listing.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-08-03
The filing discloses that Aaron Day was removed as Chief Executive Officer effective immediately on July 31, 2026, though he remains on the Board. While the filing also includes an interim CEO appointment (Joel Krutz) and a Chairman appointment (Michael Pruitt), the principal disclosed action centers on the departure of the CEO. The press release emphasizes the "leadership transition" and the Board's determination that Day "would no longer serve as Chairman of the Board and Chief Executive Officer," making the departure the salient event, though an appointment also occurred simultaneously.
View raw filing on EDGAR →
8-K
Governance Other
confidence 92%
filed 2026-08-03
The filing discloses a 1-for-10 reverse stock split approved by the board and stockholders, effective August 6, 2026. This is a governance event involving an amendment to the Articles of Incorporation under Item 5.03. While reverse stock splits are routine capital structure adjustments, this one is material because it reduces outstanding shares from ~18.1 million to ~1.8 million and directly affects share price and trading eligibility—factors relevant to investor assessment of the registrant's compliance with Nasdaq listing standards.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-03
Safe Pro Group announced a new U.S. Government subcontract award valued at approximately $730,000 for its patented AI-powered technology. This is disclosed as the "fourth recent U.S. Government award" and is characterized as expanding the company's installed base and increasing visibility into recurring software subscription revenue. While this is a material business development for a small-cap company, it does not fit neatly into the standard taxonomy categories—it is neither a major M&A transaction, a material contract in the traditional sense, nor a routine operational matter. The disclosure emphasizes growth and revenue visibility, making it a significant operational/strategic milestone rather than a one-time contract.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-03
The filing discloses the appointment of Michael J. Grissinger as a director of Lipocine Inc., effective August 3, 2026. Item 5.02 explicitly states the Board expanded to five members and appointed Mr. Grissinger as a director, with details on his compensation (2,000 share option grant and $55,000 annual retainer). The press release emphasizes his extensive pharmaceutical and M&A experience from Johnson & Johnson, positioning him as a valuable addition to advance the company's pipeline and partnerships. This is a material governance event affecting board composition.
View raw filing on EDGAR →
6-K
Financial Other
confidence 75%
filed 2026-08-03
EX-99.1
VivoPower announced the complete retirement of US$28.8 million in shareholder debt principal owed to AWN Holdings (affiliated with CEO Kevin Chin), with US$16.5 million retired through founder participation in a PIPE 2 offering and US$12.3 million paid in cash. While this involves debt elimination and capital structure simplification, it does not fit the specific categories of debt_issuance (creation of new obligation), covenant_breach, or dilutive_issuance (the PIPE 2 is a separate transaction). The core event—retirement of a material related-party debt obligation—is a significant financial transaction affecting balance sheet quality and capital structure, warranting classification as financial_other rather than a more specific type.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-08-03
The 6-K discloses that GrowHub received a Staff Determination Letter from Nasdaq on June 5, 2026, notifying the Company of delisting from The Nasdaq Capital Market due to failure to meet minimum bid price and stockholders' equity requirements. Although the Company successfully appealed and received an exception to continue listing (Decision Letter dated July 29, 2026), the core disclosure is the delisting determination and the conditional exception granted, which directly implicates Item 3.01 (Delisting or Transfer of Listing). The exception is conditioned on demonstrating compliance with initial listing standards by December 2, 2026, and the Merger's completion remains uncertain, creating material delisting risk.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 95%
filed 2026-08-03
The filing discloses that on August 3, 2026, the Audit Committee dismissed BCRG Group as the independent registered public accounting firm and appointed Simon & Edward LLP as the new auditor, effective following S&E's acquisition of BCRG's attest business on June 15, 2026. This is a clear auditor change under Item 4.01. The materiality is heightened by the disclosure that BCRG's prior audit reports contained an explanatory paragraph indicating substantial doubt about the Company's ability to continue as a going concern, making the auditor transition particularly significant to investors.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-03
Jet.AI Inc. disclosed a $1.75 million strategic equity investment in StratGrid Inc., a natural gas-powered data center developer, made through a joint venture (SG Canada InvestCo LLC) in which Jet.AI holds 60% equity. The investment gives InvestCo approximately 26% of StratGrid's common equity. This is a material strategic investment in infrastructure development that expands Jet.AI's data center portfolio capacity potential to gigawatt-scale in Alberta, Canada, but does not constitute a traditional M&A transaction (acquisition, merger, or change of control) under Item 1.01/2.01, nor does it fit other specific event categories. It is a significant operational/strategic partnership and capital deployment decision.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-03
Beeline entered into a non-binding Letter of Intent on July 28, 2026, to merge with TYTL Holdings in an all-stock business combination. Item 1.01 explicitly discloses "Entry into a Material Definitive Agreement," and the filing describes a proposed merger combining Beeline's mortgage platform with TYTL's blockchain-based real estate tokenization platform, with expected ownership split of approximately 60% Beeline and 40% TYTL stockholders. This is a material acquisition/change-of-control transaction that would materially affect the registrant's business and investor assessment.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-08-03
The filing discloses Venu Holding Corporation's entry into a Securities Purchase Agreement on July 31, 2026, for the issuance of $25,000,000 in Senior Secured Convertible Debentures with warrants to purchase 1,000,000 shares. This is a material creation of a direct financial obligation under Item 1.01, with detailed terms including maturity date (July 31, 2027), conversion rights, security interests in subsidiary assets and real property, and mandatory repayment schedules. The convertible feature and warrant component do not change the primary classification—this is fundamentally a debt issuance.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-03
The filing discloses a warrant inducement transaction in which Cycurion issued 5,012,159 unregistered New Warrants (representing 150% of exercised Existing Warrants) in a private placement to an accredited investor in exchange for the immediate exercise of existing warrants for $4.5 million in gross proceeds. This is a classic dilutive equity issuance under Item 1.01 and Item 3.02, involving unregistered securities sold in reliance on Section 4(a)(2) and Regulation D, which materially increases shareholder dilution.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-03
The 8-K discloses Ainos' financial results for the quarter ended June 30, 2026 under Item 2.02 (Results of Operations and Financial Condition), with a press release attached as Exhibit 99.1. The filing includes condensed consolidated balance sheets, statements of operations, and management commentary on Q2 2026 performance and operational highlights. This is a standard quarterly earnings release disclosure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-03
Item 7.01
The disclosure announces completion of an Interference Study for the Intelligent Fingerprinting Drug Screening System, a key regulatory milestone supporting the Company's FDA 510(k) submission planned for H2 2026. This is a material operational/product development event—the study validates system performance under real-world conditions and directly advances the Company's path to U.S. market entry in a multi-billion-dollar drug screening market. While not a specific named event type, it is clearly operational and strategic in nature, making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-03
Lantern Pharma announced the formal establishment of Open-Medicine AI as a separate company to commercialize its multi-agent AI co-scientist platform (formerly withZeta.ai), with execution of commercial licensing agreements and Board approval. This represents a significant strategic and operational restructuring—the spin-out of a material business line with dedicated funding and valuation path—but does not constitute a traditional M&A transaction, equity issuance, or other specifically-named event type. The disclosure emphasizes operational focus, market expansion, and commercial positioning rather than a change in control or divestiture.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-03
The filing discloses both the departure of Bradford Amman as CFO and the appointment of Roman Franklin as CFO, effective July 31, 2026. While both events occur, the principal disclosed action centers on the appointment of Franklin as the new CFO with a detailed background and compensatory arrangements under a Master Services Agreement with CFO Portal. The departure is presented as context for the transition. The appointment of a new CFO with material compensation terms (annual retainer of $324,000 plus equity awards) is material to investors assessing leadership and financial management continuity.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-03
Item 2.02
New Mountain Finance Corporation disclosed quarterly financial results for the period ended June 30, 2026, including adjusted net investment income of $0.26 per share and net asset value of $10.89 per share, along with a declared third-quarter distribution of $0.25 per share.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-03
Item 2.02
Kosmos Energy issued a news release on August 3, 2026, announcing financial and operating results for the second quarter ended June 30, 2026, including net income of $185 million ($0.31 per diluted share), adjusted net income of $68 million ($0.11 per diluted share), revenues of $607 million, and operational highlights.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 72%
filed 2026-08-03
Item 8.01
Bandwidth repurchased approximately $20.8 million of its 0.50% Convertible Senior Notes due 2028 in open-market transactions, reducing outstanding principal from $250 million to $6.7 million. While this is technically a debt reduction rather than issuance, the event involves a material modification of the company's direct financial obligations and capital structure. The repurchase of convertible debt at a discount to par is a significant financial event affecting the registrant's leverage and equity position.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-08-03
Item 5.02
The disclosure centers on compensatory arrangements for Mr. Marino, the Executive Vice President and Chief Financial Officer. The filing details his employment agreement effective July 30, 2026, specifying base salary ($650,000+), annual cash bonus (target 110% of base, maximum 220%), long-term equity awards, a "CFO Transformation Award" (37,500–75,000 RSUs tied to stock price and Adjusted EBITDA goals), severance provisions, and restrictive covenants. While the agreement also confirms his continued service in the CFO role, the substantive disclosure focuses on the compensation structure and equity incentives, making this an exec_compensation event rather than an appointment.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-03
Item 2.02
Diamondback Energy issued a press release on August 3, 2026 announcing financial and operating results for Q2 2026, including net income of $1.882 billion, earnings per diluted share of $6.65, production of 1,018 MBOE/d, and updated 2026 guidance. The earnings release is furnished as Exhibit 99.1 and constitutes a standard quarterly earnings disclosure under Item 2.02.
View raw filing on EDGAR →